296 related articles for article (PubMed ID: 31268980)
1. Significance of Lymph Node Metastasis in Resectable Well-differentiated Pancreatic Neuroendocrine Tumor.
Harimoto N; Hoshino K; Muranushi R; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Hosouchi Y; Suzuki H; Arakawa K; Hirai K; Fukazawa T; Ikota H; Shirabe K
Pancreas; 2019 Aug; 48(7):943-947. PubMed ID: 31268980
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of neutrophil-lymphocyte ratio in resectable pancreatic neuroendocrine tumors with special reference to tumor-associated macrophages.
Harimoto N; Hoshino K; Muranushi R; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Hosouchi Y; Suzuki H; Arakawa K; Hirai K; Fukazawa T; Ikota H; Shirabe K
Pancreatology; 2019 Sep; 19(6):897-902. PubMed ID: 31409525
[TBL] [Abstract][Full Text] [Related]
3. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
[TBL] [Abstract][Full Text] [Related]
5. Significance of lymph node metastasis in pancreatic neuroendocrine tumor.
Taki K; Hashimoto D; Nakagawa S; Ozaki N; Tomiyasu S; Ohmuraya M; Arima K; Kaida T; Higashi T; Sakamoto K; Sakata K; Okabe H; Nitta H; Hayashi H; Chikamoto A; Beppu T; Takamori H; Hirota M; Baba H
Surg Today; 2017 Sep; 47(9):1104-1110. PubMed ID: 28229300
[TBL] [Abstract][Full Text] [Related]
6. The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management.
Lopez-Aguiar AG; Ethun CG; Zaidi MY; Rocha FG; Poultsides GA; Dillhoff M; Fields RC; Idrees K; Cho CS; Abbott DE; Cardona K; Maithel SK
Surgery; 2019 Jul; 166(1):15-21. PubMed ID: 31072670
[TBL] [Abstract][Full Text] [Related]
7. CD47 expression and CD163
Imam R; Chang Q; Black M; Yu C; Cao W
BMC Cancer; 2021 Mar; 21(1):320. PubMed ID: 33765961
[TBL] [Abstract][Full Text] [Related]
8. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
[TBL] [Abstract][Full Text] [Related]
9. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
[TBL] [Abstract][Full Text] [Related]
10. Diffusion-Weighted MRI Predicts Lymph Node Metastasis and Tumor Aggressiveness in Resectable Pancreatic Neuroendocrine Tumors.
Harimoto N; Araki K; Hoshino K; Muranushi R; Hagiwara K; Ishii N; Tsukagoshi M; Igarashi T; Watanabe A; Kubo N; Tomonaga H; Higuchi T; Tsushima Y; Ikota H; Shirabe K
World J Surg; 2020 Dec; 44(12):4136-4141. PubMed ID: 32797282
[TBL] [Abstract][Full Text] [Related]
11. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs).
Partelli S; Gaujoux S; Boninsegna L; Cherif R; Crippa S; Couvelard A; Scarpa A; Ruszniewski P; Sauvanet A; Falconi M
JAMA Surg; 2013 Oct; 148(10):932-9. PubMed ID: 23986355
[TBL] [Abstract][Full Text] [Related]
12. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
[TBL] [Abstract][Full Text] [Related]
13. Predictive Factors for Lymph Node Metastasis and Prognostic Factors for Survival in Rectal Neuroendocrine Tumors.
Sohn B; Kwon Y; Ryoo SB; Song I; Kwon YH; Lee DW; Moon SH; Park JW; Jeong SY; Park KJ
J Gastrointest Surg; 2017 Dec; 21(12):2066-2074. PubMed ID: 29047070
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine tumor G3: a pancreatic well-differentiated neuroendocrine tumor with a high proliferative rate.
Tanaka H; Matsusaki S; Baba Y; Isono Y; Kumazawa H; Sase T; Okano H; Saito T; Mukai K; Kaneko H
Clin J Gastroenterol; 2015 Dec; 8(6):414-20. PubMed ID: 26439620
[TBL] [Abstract][Full Text] [Related]
15. Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤2 cm after curative resection: A multi-institutional study of 392 cases.
Dong DH; Zhang XF; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Pawlik TM;
J Surg Oncol; 2019 Dec; 120(7):1071-1079. PubMed ID: 31571225
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.
Zhang P; Li YL; Qiu XD; Luo J; Shi YF; Sun YL; Su F; Qi ZR; Tan HY
World J Surg Oncol; 2019 Apr; 17(1):66. PubMed ID: 30975157
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis.
Poultsides GA; Huang LC; Chen Y; Visser BC; Pai RK; Jeffrey RB; Park WG; Chen AM; Kunz PL; Fisher GA; Norton JA
Ann Surg Oncol; 2012 Jul; 19(7):2295-303. PubMed ID: 22396008
[TBL] [Abstract][Full Text] [Related]
18. A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors.
Sho S; Court CM; Winograd P; Toste PA; Pisegna JR; Lewis M; Donahue TR; Hines OJ; Reber HA; Dawson DW; Tomlinson JS
J Gastrointest Surg; 2019 Jul; 23(7):1392-1400. PubMed ID: 30353489
[TBL] [Abstract][Full Text] [Related]
19. Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors.
Tan QQ; Wang X; Yang L; Chen YH; Tan CL; Zhu XM; Ke NW; Liu XB
Medicine (Baltimore); 2020 Jun; 99(24):e20324. PubMed ID: 32541455
[TBL] [Abstract][Full Text] [Related]
20. Outcome of surgery for pancreatic neuroendocrine neoplasms.
Fischer L; Bergmann F; Schimmack S; Hinz U; Prieß S; Müller-Stich BP; Werner J; Hackert T; Büchler MW
Br J Surg; 2014 Oct; 101(11):1405-12. PubMed ID: 25132004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]